On the affordability piece, just opening the market doesn't mean that the prices are going to go down, because the main aim of the pharmaceutical companies—and they're the ones who drew up the TPP agreement—is to keep the patents on medications, which keeps the medications at higher prices. If Canada, for example, were to stop a patent, as they are doing with Eli Lilly, for example, then they are sued under ISDS.
We don't foresee it. We hope against hope. It would be nice if they decreased, but they will not. NAFTA has shown that the medication prices just....